Hematologic Cancers
Hematologic Cancers News & Features
Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.
The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.
Rusfertide demonstrated activity in reducing hematocrit levels in patients with polycythemia vera in two phase 2 clinical trials.
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Next post in Hematologic Cancers
Loading...
Loading...